Download PDF
Suchttherapie 2002; 3(Suppl. 1): S37-S44
DOI: 10.1055/s-2002-32765
Orginalarbeit
© Georg Thieme Verlag Stuttgart · New York

Virologische und immunologische Grundlagen der Therapie der chronischen HCV-Infektion

Virologic and Immunologic Backgrounds for the Treatment of Chronic Hepatitis C Virus InfectionChristoph Sarrazin, Stefan Zeuzem
  • 1Medizinische Klinik II, Johann Wolfgang Goethe-Universität Frankfurt am Main
Further Information

Publication History

Publication Date:
11 July 2002 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Das Hepatitis-C-Virus (HCV) ist ein hepatotropes Einzel-(+)Strang RNA-Virus, das häufig zu einer chronischen Leberentzündung führt und mit dem Risiko der Entwicklung einer Leberzirrhose und eines Leberzellkarzinoms assoziiert ist. Das HCV kodiert für drei strukturelle (Kapsid, Hüllprotein 1 und 2) und 6 nicht strukturelle Proteine (NS2, 3, 4A, 4B, 5A und 5B). Bei der HCV-Infektion werden Antikörper gegen eine hypervariable Region des Hüllproteins 2 ausgebildet, die vermutlich neutralisierende Eigenschaften haben. Bei der T-Zellantwort scheint die CD4-positive, von TH1-Zellen getragene Immunantwort von besonderer Bedeutung für den Verlauf der akuten Infektion und einer antiviralen Therapie zu sein. Die Therapie mit Interferon-alpha wird über antivirale, antiproliferative und immunmodulatorische Effekte vermittelt. Die antiviralen Wirkungen des Nukleosidanalogons Ribavirin gegenüber dem HCV sind noch nicht vollständig verstanden. Das Hüllprotein 2 (E2) sowie das NS5A-Protein scheinen für Therapieresistenzmechanismen des HCV verantwortlich zu sein. Bei In-vitro-Untersuchungen fand sich eine Hemmung der Interferon-alpha induzierten Doppelstrang-RNA-abhängigen Proteinkinase (PKR) durch Bindung an eine spezifische Region des E2- und NS5A-Proteins. Klinisch sind Mutationen im Bereich des NS5A-, nicht aber des E2-Proteins mit dem Ansprechen auf eine antivirale Therapie mit Interferon-alpha und Ribavirin korreliert.

Abstract

Hepatitis C virus (HCV) is a positive single-strand RNA virus leading to chronic hepatitis with subsequent development of cirrhosis and its sequelae. HCV is coding for 3 structural (core, envelope 1 and 2) and 6 non-structural proteins (NS2, 3, 4A, 4B, 5A and 5B). Antibodies developing against the hypervariable region 1 within envelope 2 protein have neutralising effects. T cell response of CD4 positive TH1-cells is important for recovery from acute HCV infection as well as for response to antiviral therapy. Treatment of chronic HCV infection with interferon-alpha is mediated through antiviral, antiproliferative and immunomodulatory effects. Antiviral effects of the nucleoside analog ribavirin are not yet fully understood. Envelope protein 2 (E2) as well as the NS5A protein seem to be involved in interferon-alpha resistance mechanisms of HCV. Interferon-alpha induced double-strand RNA dependent proteinkinase (PKR) is inhibited in vitro due to specific binding of E2 and NS5A protein. Clinically mutations within the NS5A protein but not within the E2 protein are positively correlated with response to interferon-alpha and ribavirin combination therapy.

Schlüsselwörter

Hepatitis-C-Virus - Molekularbiologie - Interferon-alpha - Ribavirin - Therapieresistenz

Key words

Hepatitis C Virus - Molecular Biology - Interferon-Alpha - Ribavirin - Treatment Resistance Mechanism

Literatur

  • 1 Classification and nomenclature of viruses: sixth report of the international committee on taxonomy of viruses. Murphy FA, Fauquet CM, Bishop DHL, Ghabrial SA, Jarvis AW, Martelli GP, Mayo MA, Summers MD Wien; Springer 1995: 424-426
    Search in Google Scholar
  • 2 Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions.  J Virol. 1993;  67 3835-3844
    Search in Google Scholar
  • 3 Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Kincetic and structural analyses of hepatitis C virus polyprotein processing.  J Virol. 1994;  68 5045-5055
    Search in Google Scholar
  • 4 Rijnbrand R C, Lemon S M. Internal ribosome entry site-mediated translation in hepatitis C virus replication.  Curr Top Microbiol Immunol. 2000;  242 85-116
    Search in Google Scholar
  • 5 Bartenschlager R, Lohmann V. Replication of hepatitis C virus.  J Gen Virol. 2000;  81 1631-1648
    Search in Google Scholar
  • 6 Reed K E, Rice C M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties.  Curr Top Microbiol Immunol. 2000;  242 55-84
    Search in Google Scholar
  • 7 Zeuzem S, Roth W K, Herrmann G. Virushepatitis C.  Z Gastroenterol. 1995;  33 117-132
    Search in Google Scholar
  • 8 Kurosaki M, Enomoto N, Marumo F, Sato C. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C.  Virology. 1994;  233 43-50
    Search in Google Scholar
  • 9 Ogata N, Alter H J, Miller R H, Purcell R H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.  Proc Natl Acad Sci USA. 1991;  88 3392-3396
    Search in Google Scholar
  • 10 Gomez J, Martell M, Quer J, Cabot B, Esteban J I. Hepatitis C viral quasispecies.  J Viral Hepat. 1999;  6 3-16
    Search in Google Scholar
  • 11 Simmonds P. Variability of hepatitis C virus.  Hepatology. 1995;  21 570-583
    Search in Google Scholar
  • 12 Martell M, Esteban J I, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.  J Virol. 1992;  66 3225-3229
    Search in Google Scholar
  • 13 Simmonds P, Holmes E C, Cha T A, McOmish F, Irvine B, Beall E, Yap P L, Kolberg J, Urdea M S. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region.  J Gen Virol. 1993;  74 2391-2399
    Search in Google Scholar
  • 14 Simmonds P. Virology of hepatitis C virus.  Clin Ther. 1996;  18 (Suppl B) 9-36
    Search in Google Scholar
  • 15 Schreier E, Roggendorf M, Driesel G, Hohne M, Viazov S. Genotypes of hepatitis C virus isolates from different parts of the world.  Arch Virol. 1996;  11 185-193 (Suppl)
    Search in Google Scholar
  • 16 Kato N, Hijikata M, Ootsuma Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.  Proc Natl Acad Sci USA. 1990;  87 9524-9528
    Search in Google Scholar
  • 17 Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi S I, Ichikawa M, Kajita T, Moradpour D, Wands J R, Kohara M. The native form and maturation process of hepatitis C virus core protein.  J Virol. 1998;  72 6048-6055
    Search in Google Scholar
  • 18 Lai M M, Ware C F. Hepatitis C virus core protein: possible roles in viral pathogenesis.  Curr Top Microbiol Immunol. 2000;  242 117-134
    Search in Google Scholar
  • 19 Xu Z, Choi J, Yen T SB, Lu W, Strohecker A, Govindarajan S, Chien D, Selby M J, Ou J. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift.  EMBO. 2001;  20 3840-3848
    Search in Google Scholar
  • 20 Dubuisson J. Folding, assembly and subcellular localization of hepatitis C virus glycoproteins.  Curr Top Microbiol Immunol. 2000;  242 135-148
    Search in Google Scholar
  • 21 Deleersnyder V, Pillez A, Wychowski C, Blight K, Xu J, Hahn Y S, Rice C M, Dubuisson J. Formation of native hepatitis C vius glycoprotein complexes.  J Virol. 1997;  71 697-704
    Search in Google Scholar
  • 22 Kato N, Ootsuyama Y, Tanaka T, Nakagawa M, Nakazawa T, Muraiso K, Ohkoshi S, Hijikata M, Shimotohno K. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses.  Virus Res. 1992;  22 107-123
    Search in Google Scholar
  • 23 Weiner A J, Brauer M J, Rosenblatt J, Richman K H, Tung J, Crawford K, Bonino F, Saracco G, Choo Q L, Houghton M. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins.  Virology. 1991;  180 842-848
    Search in Google Scholar
  • 24 Kurosaki M, Enomoto N, Marumo F, Sato C. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection.  Hepatology. 1993;  18 1293-1299
    Search in Google Scholar
  • 25 Kato N, Ootsuyama Y, Sekiya H, Ohkoshi S, Nakazawa T, Hijikata M, Shimotohno K. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection.  J Virol. 1994;  68 4776-4784
    Search in Google Scholar
  • 26 Mizushima H, Hijikata M, Asabe S I, Hirota M, Kimura K, Shimotohno K. Two hepatitis C virus glycoprotein E2 products with different C termini.  J Virol. 1994;  68 6215-6222
    Search in Google Scholar
  • 27 Mizushima H, Hijikata M, Tanji Y, Kimura K, Shimotohno K. Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2.  J Virol. 1994;  68 2731-2734
    Search in Google Scholar
  • 28 Grakoui A, McCourt D W, Wychowski C, Feinstone S M, Rice C M. A second hepatitis C virus-encoded proteinase.  Proc Natl Acad Sci USA. 1993;  90 10583-10587
    Search in Google Scholar
  • 29 Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus.  J Virol. 1993;  67 4665-4675
    Search in Google Scholar
  • 30 Love A L, Parge H E, Wickersham J A, Hostomsky Z, Habuka N, Moomaw E W, Adachi T, Hostomska Z. The crystal stucture of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.  Cell. 1996;  87 342
    Search in Google Scholar
  • 31 Grakoui A, McCourt D W, Wychowski C, Feinstone S M, Rice C M. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites.  J Virol. 1993;  67 2832-2843
    Search in Google Scholar
  • 32 Preugschat F, Averett D R, Clarke B E, Porter D JT. A steady state and pre-stady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain.  J Biol Chem. 1996;  271 24449-24457
    Search in Google Scholar
  • 33 Suzich J A, Tamura J K, Palmer-Hill F, Warrener P, Grakoui A, Rice C M, Feinstone S M, Collett M S. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes.  J Virol. 1993;  67 6152-6158
    Search in Google Scholar
  • 34 Tai C L, Chi W K, Chen D S, Hwang L H. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3).  J Virol. 1996;  70 8477-8484
    Search in Google Scholar
  • 35 Di Marco S, Rizzi M, Volpari C, Walsh M A, Narjes F, Colarusso S, De Francesco R, Matassa V G, Sollazzo M. Inhibition of the Hepatitis C Virus NS3/4A Protease. The crystal structures of two protease-inhibitor complexes.  J Biol Chem. 2000;  275 7152-7157
    Search in Google Scholar
  • 36 Lin C, Wu J W, Hsiao K, Su M SS. The hepatitis C virus NS4A protein: interactions with the NS4B and NS5A protein.  J Virol. 1997;  71 6465-6471
    Search in Google Scholar
  • 37 Koch O J, Bartenschlager R. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B.  J Virol. 1999;  73 7138-7146
    Search in Google Scholar
  • 38 Kaneko T, Tanji Y, Satoh S, Hijikata M, Asabe S, Kimura K, Shimotohno K. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome.  Biochem Biophys Res Commun. 1994;  205 320-326
    Search in Google Scholar
  • 39 Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A.  J Virol. 1995;  69 3980-3986
    Search in Google Scholar
  • 40 Hu K Q, Vierling J M, Redeker A G. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.  J Viral Hepat. 2001;  8 1-18
    Search in Google Scholar
  • 41 Pawlotsky J M. Hepatitis C virus resistance to antiviral therapy.  Hepatology. 2000;  32 889-896
    Search in Google Scholar
  • 42 Tan S L, Katze M G. How Hepatitis C Virus Counteracts the Interferon Response: The Jury Is Still out on NS5A.  Virology. 2001;  284 1-12
    Search in Google Scholar
  • 43 Pawlotsky J M, Germanidis G. The non-structural 5A protein of hepatitis C virus.  J Viral Hepat. 1999;  6 343-356
    Search in Google Scholar
  • 44 Lohmann V, Roos A, Korner F, Koch J O, Bartenschlager R. Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.  J Viral Hepat. 2000;  7 167-174
    Search in Google Scholar
  • 45 Lohmann V, Körner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity.  J Virol. 1997;  71 8416-8428
    Search in Google Scholar
  • 46 Yuan Z H, Kumar U, Thomas H C, Wen Y M, Monjardino J. Expression, purification, and partial charactarization of HCV RNA polymerase.  Biochem Biophys Res Commun. 1997;  232 231-235
    Search in Google Scholar
  • 47 Yamashita T, Kaneko S, Shirota Y, Qin W, Nomura T, Kobayashi K, Murakami S. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region.  J Biol Chem. 1998;  273 15479-15486
    Search in Google Scholar
  • 48 Behrens S E, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus.  EMBO. 1996;  15 12-22
    Search in Google Scholar
  • 49 Al R H, Xie Y, Wang Y, Hagedorn C H. Expression of recombinant hepatitis C virus non-structural protein 5B in Escherichia coli.  Virus Res. 1998;  53 141-149
    Search in Google Scholar
  • 50 Lau J Y, Mizokami M, Davis G L, Kolberg J A, Urdea M S, Orito E, Polito A, DiNello R, Quan S. Relationship between the presence of circulating anti-GOR and hepatitis C viremia/genotype.  J Hepatol. 1995;  22 707
    Search in Google Scholar
  • 51 Taliani G, Lecce R, Badolato M C, Bozza A, Poliandri G, Furlan C, Bruni R, Clementi C, De Bac C. Anti-GOR antibodies in anti-hepatitis C virus positive subjects with and without virus replication and liver disease.  J Hepatol. 1994;  20 845
    Search in Google Scholar
  • 52 Shimizu Y K, Hijikata M, Iwamoto A, Alter H J, Purcell R H, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.  J Virol. 1994;  68 1494-1500
    Search in Google Scholar
  • 53 Quiroga J A, van Binsbergen J, Wang C Y, Pardo M, Navas S, Trines C, Herrero M, Carreno V. Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome.  Hepatology. 1995;  22 1635-1640
    Search in Google Scholar
  • 54 Quiroga J A, Campillo M L, Catillo I, Bartolome J, Porres J C, Carreno V. IgM antibody to hepatitis C virus in acute and chronic hepatitis C.  Hepatology. 1991;  14 38-43
    Search in Google Scholar
  • 55 Gerlach J T, Diepolder H M, Jung M C, Gruener N H, Schraut W W, Zachoval R, Hoffmann R, Schirren C A, Santantonio T, Pape G R. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.  Gastroenterology. 1999;  117 933-941
    Search in Google Scholar
  • 56 Grüner N H, Gerlach T J, Jung M C, Diepolder H M, Schirren C A, Schraut W W, Hoffmann R, Zachoval R, Santantonio T, Cucchiarini M, Cerny A, Pape G R. Association of Hepatitis C Virus-Specific CD8+ T Cells with Viral Clearance in Acute Hepatitis C.  J Infect Dis. 2000;  181 1528-1536
    Search in Google Scholar
  • 57 Rehermann B, Chang K M, McHutchison J G, Kokka R, Houghton M, Chisari F V. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.  J Clin Invest. 1996;  98 1432-1440
    Search in Google Scholar
  • 58 Rehermann B, Chang K M, McHutchison J, Kokka R, Houghton M, Rice C M, Chisari F V. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.  J Virol. 1996;  70 7092-7102
    Search in Google Scholar
  • 59 Grüner N H, Lechner F, Jung M C, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape G R, Klenerman P. Sustained dysfunction of antiviral cd8(+) t lymphocytes after infection with hepatitis c virus.  J Virol. 2001;  75 5550-5558
    Search in Google Scholar
  • 60 Cabot B, Martell M, Esteban J I, Sauleda S, Otero T, Esteban R, Guardia J, Gomez J. Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver.  J Virol. 2000;  74 805-811
    Search in Google Scholar
  • 61 Rehermann B, Chisari F V. Cell mediated immune response to the hepatitis C virus.  Curr Top Microbiol Immunol. 2000;  242 299-325
    Search in Google Scholar
  • 62 Diepolder H M, Hoffmann R M, Gerlach J T, Zachoval R, Jung M C, Pape G R. Immunopathogenesis of HCV infection.  Curr Stud Hematol Blood Transfus. 1998;  135-151
    Search in Google Scholar
  • 63 Owerbach D, Rutter W J, Shows T B, Gray P, Goeddel D V, Lawn R M. Leukocyte and fibroblast interferon genes are located on human chromosome 9.  Proc Natl Acad Sci USA. 1981;  78 3123-3127
    Search in Google Scholar
  • 64 Foster G R, Rodrigues O, Ghouze F, Schulte-Frohlinde E, Testa D, Liao M J, Stark G R, Leadbeater L, Thomas H C. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency.  J Interferon Cytokine Res. 1996;  16 1027-1033
    Search in Google Scholar
  • 65 Pestka S, Langer J A, Zoon K C, Samuel C E. Interferons and their actions.  Annu Rev Biochem. 1987;  56 727-777
    Search in Google Scholar
  • 66 Lengyel P. Biochemistry of interferons and their actions.  Annu Rev Biochem. 1982;  51 251-282
    Search in Google Scholar
  • 67 Pfeffer L M, Dinarello C A, Heberman R B, Williams B RG, Borden E C, Bordens R, Walter M R, Nagabhushan T L, Trotta P P, Pestka S. Biological properties of recombinant a-interferons: 40th anniversary of the discovery of interferons.  Cancer Res. 1998;  58 2489-2499
    Search in Google Scholar
  • 68 Farrell G C, Bacon B R, Goldin R D. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.  Hepatology. 1998;  27 1121-1127
    Search in Google Scholar
  • 69 Cacopardo B, Benanti F, Brancati G, Romano F, Nunnari A. Leucocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons.  J Viral Hepat. 1998;  5 333-339
    Search in Google Scholar
  • 70 Isaacs A, Lindenmann J. Virus interference. I. The interferon.  Proc R Soc Lond Ser B. 1957;  147 258-267
    Search in Google Scholar
  • 71 Stark G R, Kerr I M, Williams B RG, Silverman R H, Schreiber R D. How cells respond to interferons.  Annu Rev Biochem. 1998;  67 227-264
    Search in Google Scholar
  • 72 Witkowski J T, Robins R K, Sidwell R W, Simon L N. Design, synthesis, and broad spectrum antiviral activity of 1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides.  J Med Chem. 1972;  15 1150-1154
    Search in Google Scholar
  • 73 Sidwell R W, Huffman J H, Khare G P, Allen L B, Witkowski J T, Robins R K. Broad-spectrum antiviral activity of Virazole: 1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.  Science. 1972;  177 705-706
    Search in Google Scholar
  • 74 Glue P. The clinical pharmacology of ribavirin.  Semin Liv Dis. 1999;  19 (Suppl 1) 17-24
    Search in Google Scholar
  • 75 Chang T W, Heel R C. Ribavirin and inosiplex: a review of their present status in viral diseases.  Drugs. 1981;  22 111-128
    Search in Google Scholar
  • 76 Goswami B B, Borek E, Sharma O K, Fujitaki J, Smith R A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.  Biochem Biophys Res Commun. 1979;  89 830-836
    Search in Google Scholar
  • 77 Wray S K, Gilbert B E, Noall M W, Knight V. Mode of action of ribavirin: effect of nucleotide pool alteration on influenza virus ribonucleoprotein synthesis.  Antiviral Res. 1985;  5 29-37
    Search in Google Scholar
  • 78 Eriksson B, Helgstrand E, Johansson N G, Larsson A, Misiorny A, Noren J O, Philipson L, Sternberg K, Stening G, Stridh S, Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate.  Antimicrob Agents Chemother. 1977;  11 946-951
    Search in Google Scholar
  • 79 Peavy D L, Powers C N, Knight V. Inhibition of murine plaque-forming cell responses in vivo by ribavirin.  J Immunol. 1981;  126 861-864
    Search in Google Scholar
  • 80 Powers C N, Peavy D L, Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin.  Antimicrob Agents Chemother. 1982;  22 108-114
    Search in Google Scholar
  • 81 Hultgren C, Milich D R, Weiland O, Sällberg M. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune response.  J Gen Virol. 1998;  79 2381-2391
    Search in Google Scholar
  • 82 Di Bisceglie A M, Conjeevaram H S, Fried M W, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner D E, Mahaney K, Hoofnagle J H. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1995;  123 897-903
    Search in Google Scholar
  • 83 Zeuzem S, Schmidt J M, Lee J H, von Wagner M, Teuber G, Roth W K. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.  Hepatology. 1998;  28 245-252
    Search in Google Scholar
  • 84 Lee J H, von Wagner M, Roth W K, Teuber G, Sarrazin C, Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus.  J Hepatol. 1998;  29 29-35
    Search in Google Scholar
  • 85 Fried M W, Fong T L, Swain M G, Park Y, Beames M P, Banks S M, Hoofnagle J H, Di Bisceglie A M. Therapy of chronic hepatitis B with a 6-month course of ribavirin.  J Hepatol. 1994;  21 145-150
    Search in Google Scholar
  • 86 Poynard T, Marcellin P, Lee S S, Niederau C, Minuk G S, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).  Lancet. 1998;  352 1426-1432
    Search in Google Scholar
  • 87 Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.  N Engl J Med. 1996;  334 77-81
    Search in Google Scholar
  • 88 Zeuzem S, Lee J H, Roth W K. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.  Hepatology. 1997;  25 740-744
    Search in Google Scholar
  • 89 Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, Pol S, Brechot C. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.  Gastroenterology. 1997;  113 567-572
    Search in Google Scholar
  • 90 Hofgärtner W T, Polyak S J, Sullivan D G, Carithers Jr R L, Gretch D R. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.  J Med Virol. 1997;  53 118-126
    Search in Google Scholar
  • 91 Sarrazin C, Berg T, Lee J H, Teuber G, Dietrich C F, Roth W K, Zeuzem S. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.  J Hepatol. 1999;  30 1004-1013
    Search in Google Scholar
  • 92 Sarrazin C, Berg T, Lee J H, Rüster B, Kronenberger B, Roth W K, Zeuzem S. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response.  J Infect Dis. 2000;  181 432-441
    Search in Google Scholar
  • 93 Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection.  Hepatology. 1999;  30 1045-1053
    Search in Google Scholar
  • 94 Sarrazin C, Kornetzky I, Rüster B, Lee J H, Kronenberger B, Bruch K, Roth W K, Zeuzem S. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.  Hepatology. 2000;  31 1360-1370
    Search in Google Scholar
  • 95 Gale Jr M, Blakely C M, Kwieciszewski B, Tan S L, Dossett M, Tang N M, Korth M J, Polyak S J, Gretch D R, Katze M G. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation.  Mol Cell Biol. 1998;  18 5208-5218
    Search in Google Scholar
  • 96 Polyak S J, Paschal D M, McArdle S, Gale M J Jr, Moradpour D, Gretch D R. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication.  Hepatology. 1999;  29 1262-1271
    Search in Google Scholar
  • 97 Paterson M, Laxton C D, Thomas H C, Ackrill A M, Foster G R. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response.  Gastroenterology. 1999;  117 1187-1197
    Search in Google Scholar
  • 98 Francois C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum H E, Gatignol A, Wychowski C, Moradpour D, Meurs E F. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis.  J Virol. 2000;  74 5587-5596
    Search in Google Scholar
  • 99 Taylor D R, Shi S T, Romano P R, Barber G N, Lai M MC. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.  Science. 1999;  285 107-110
    Search in Google Scholar

Dr. med. Christoph Sarrazin

Johann Wolfgang Goethe-Universität Frankfurt am Main, Medizinische Klinik II

Theodor-Stern-Kai 7

60590 Frankfurt am Main

Email: sarrazin@em.uni-frankfurt.de